Before the clinical setback, Evommune shares traded above $22. The failure to achieve the mean change in UAS7 at 12 weeks effectively stripped the company of its most advanced regulatory catalyst. While management intends to pivot development of EVO756 toward atopic dermatitis and migraine treatments, the market reaction reflects the loss of significant shareholder value.
Evommune Investors Face Scrutiny Following Phase 2b Trial Failure
A 38% single-session collapse in Evommune, Inc. shares has triggered a securities fraud investigation by law firm Levi & Korsinsky. The sharp devaluation followed the company’s announcement on June 29, 2026, that its lead drug candidate, EVO756, failed to meet primary endpoints in a Phase 2b clinical trial for chronic spontaneous urticaria.
Levi & Korsinsky is currently evaluating whether the company issued misleading statements regarding the drug's clinical prospects. The firm is encouraging investors who purchased stock and incurred losses to contact attorney Joseph E. Levi at (212) 363-7500 or via email. Participation in the investigation is open to both current and former shareholders, including international investors who traded on U.S. exchanges, with all reviews conducted on a contingency basis.
Comments (0)
No comments yet. Be the first!